BRIEF-Genentech says FDA approves Rituxan Hycela for subcutaneous injection in certain blood cancers
* FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
March 23 Spineguard SA:
* FY net loss EUR 4.2 million ($4.53 million)versus loss of EUR 3.9 million year ago Source text for Eikon:, see also Further company coverage: ($1 = 0.9275 euros) (Gdynia Newsroom)
AMSTERDAM, June 22 Mylan NV shareholders voted against the generic drugmaker's executive pay policy but re-elected the board at its annual meeting on Thursday despite a shareholder campaign in the wake of a scandal over high prices for its EpiPen emergency allergy treatment.